Darunavir Accord

What Is Darunavir Accord and What Is It Used For?

Darunavir Accord is a prescription antiretroviral medicine used to treat HIV-1 (Human Immunodeficiency Virus type 1) infection. It belongs to a class of HIV medicines called protease inhibitors (PIs) and works by blocking the HIV protease enzyme, which the virus needs to produce mature, infectious viral particles. Darunavir must always be taken with a pharmacokinetic enhancer and other HIV medicines.

Darunavir, the active substance in Darunavir Accord, was developed as a second-generation protease inhibitor with the specific aim of overcoming resistance mutations that had limited the efficacy of earlier drugs in this class, such as indinavir, nelfinavir, and lopinavir. Approved by the U.S. Food and Drug Administration (FDA) in 2006 and subsequently by the European Medicines Agency (EMA), darunavir rapidly became one of the most widely used protease inhibitors worldwide due to its potent antiviral activity and high genetic barrier to resistance.

Darunavir Accord is a generic formulation manufactured by Accord Healthcare. It contains the same active substance as the originator product and has been shown to be bioequivalent, meaning it delivers the same amount of darunavir to the bloodstream. Generic antiretroviral medicines play a crucial role in expanding global access to HIV treatment, particularly in resource-limited settings where cost is a major barrier to therapy.

The medicine is indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged 3 years and older weighing at least 15 kilograms. It must always be used in combination with a pharmacokinetic enhancer — either low-dose ritonavir (100 mg) or cobicistat (150 mg) — and other antiretroviral agents. This combination approach, known as combination antiretroviral therapy (cART), targets multiple stages of the HIV life cycle simultaneously, providing more durable viral suppression and reducing the risk of resistance development.

It is important to understand that darunavir does not cure HIV infection. However, when taken consistently as part of an effective antiretroviral regimen, it can reduce the amount of virus in the blood (viral load) to undetectable levels, preserve and restore immune function (as measured by CD4+ T-cell counts), prevent progression to AIDS, and substantially reduce the risk of HIV transmission to others. The concept of “undetectable equals untransmittable” (U=U) has been firmly established by large clinical studies and is endorsed by the World Health Organization (WHO) and all major HIV treatment guidelines.

What Should You Know Before Taking Darunavir Accord?

Before starting Darunavir Accord, your doctor needs to know about all your medical conditions, especially liver disease (including hepatitis B or C), hemophilia, diabetes, sulfonamide allergy, and all other medicines you take. Darunavir has many drug interactions and certain medicines are strictly contraindicated when taken together.

Contraindications

Darunavir Accord must not be used in the following situations:

• Hypersensitivity: Known allergy to darunavir or any of the excipients in the tablet formulation. Darunavir contains a sulfonamide moiety; use caution in patients with known sulfonamide allergy, although cross-reactivity is considered low.
• Severe hepatic impairment: Darunavir is contraindicated in patients with severe liver disease (Child-Pugh Class C), as it is extensively metabolized by the liver and drug levels may be unpredictable.
• Co-administration with certain drugs: Darunavir must not be combined with medicines that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations could lead to serious or life-threatening events. These include rifampicin, ergot derivatives (dihydroergotamine, ergotamine, ergonovine, methylergonovine), oral midazolam, triazolam, simvastatin, lovastatin, St John’s Wort (Hypericum perforatum), sildenafil when used for pulmonary arterial hypertension, and certain antiarrhythmics (amiodarone, dronedarone).

Warnings and Precautions

Several important safety considerations apply to the use of Darunavir Accord:

• Hepatotoxicity: Drug-induced hepatitis and hepatic failure have been reported in patients receiving darunavir. Patients with pre-existing liver disease, including chronic hepatitis B or C, are at increased risk. Liver function tests (ALT, AST, bilirubin) should be performed before initiating therapy and monitored at regular intervals. If liver enzyme elevations occur, treatment interruption or discontinuation should be considered.
• Skin reactions: Rash, including maculopapular rash and erythema multiforme, has been reported. Rare cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) have occurred. Discontinue treatment immediately if signs of severe skin reaction develop.
• Immune reconstitution inflammatory syndrome (IRIS): When antiretroviral therapy is started, the recovering immune system may produce an inflammatory response to previously subclinical opportunistic infections (such as Mycobacterium avium complex, cytomegalovirus, Pneumocystis jirovecii, or tuberculosis). This may require additional treatment and monitoring.
• Metabolic effects: Protease inhibitors, including darunavir, have been associated with increases in total cholesterol, LDL cholesterol, and triglycerides, as well as hyperglycemia and new-onset or worsening diabetes mellitus. Lipid levels and blood glucose should be monitored.
• Hemophilia: Increased bleeding, including spontaneous skin hematomas and hemarthrosis, has been reported in patients with hemophilia type A and B receiving protease inhibitors.
• Fat redistribution: Combination antiretroviral therapy has been associated with redistribution and accumulation of body fat (lipodystrophy), including central obesity, peripheral wasting, breast enlargement, and dorsocervical fat accumulation (buffalo hump).
• Osteonecrosis: Cases of osteonecrosis have been reported, particularly in patients with advanced HIV disease and/or long-term antiretroviral exposure.

Pregnancy and Breastfeeding

Darunavir may be used during pregnancy when the potential benefit justifies the potential risk to the fetus. International guidelines, including the DHHS Perinatal HIV Guidelines and the European AIDS Clinical Society (EACS) guidelines, include darunavir/ritonavir as an alternative protease inhibitor-based regimen in pregnancy. However, pharmacokinetic studies have demonstrated reduced darunavir exposure during the second and third trimesters, potentially requiring dose adjustments and more frequent viral load monitoring.

Breastfeeding is not recommended for women living with HIV in high-income settings, regardless of antiretroviral treatment, due to the risk of postnatal HIV transmission. In settings where safe replacement feeding is not available, WHO guidelines recommend that mothers receiving antiretroviral therapy should breastfeed for at least 12 months, as the benefits of breastfeeding may outweigh the risks of HIV transmission when the mother is virologically suppressed.

How Does Darunavir Accord Interact with Other Drugs?

Darunavir is both a substrate and an inhibitor of cytochrome P450 3A (CYP3A), and co-administration with a pharmacokinetic enhancer (ritonavir or cobicistat) further increases the inhibition of CYP3A. This leads to many clinically significant drug interactions. Always inform your doctor and pharmacist about all medicines, supplements, and herbal products you are taking.

Drug interactions are one of the most critical considerations when prescribing darunavir-based regimens. Because darunavir requires boosting with ritonavir or cobicistat — both potent CYP3A4 inhibitors — the combination can dramatically increase or decrease plasma levels of co-administered drugs that are metabolized by CYP3A. Some interactions may lead to loss of therapeutic effect of either darunavir or the co-administered drug, while others may result in dangerous toxicity.

The table below summarizes the most clinically important drug interactions. This list is not exhaustive, and healthcare providers should consult a comprehensive interaction database before initiating or changing co-medications.

Major Interactions (Contraindicated)

Notable Interactions Requiring Dose Adjustment or Monitoring

What Is the Correct Dosage of Darunavir Accord?

The dosage of Darunavir Accord depends on whether the patient is treatment-naive or treatment-experienced, and on body weight in pediatric patients. It must always be taken with food and with a pharmacokinetic enhancer (ritonavir or cobicistat). Never change your dose without consulting your doctor.

Proper dosing of darunavir is essential for maintaining viral suppression and preventing the emergence of resistance. The dosing regimen depends on prior treatment history and the presence of darunavir resistance-associated mutations. In all cases, darunavir must be taken with food, as food increases the bioavailability of darunavir by approximately 30%. Taking darunavir on an empty stomach may result in subtherapeutic drug levels and treatment failure.

Adults

Children (3 Years and Older, ≥15 kg)

Pediatric dosing is based on body weight and must be determined by the prescribing physician. Darunavir should be given with low-dose ritonavir as the pharmacokinetic enhancer. The recommended doses are:

For treatment-experienced children with darunavir resistance mutations, a twice-daily regimen based on body weight should be used. The prescribing physician will determine the appropriate dose.

Elderly Patients

There is limited clinical data on the use of darunavir in patients aged 65 years and older. No specific dose adjustment is recommended based on age alone. However, elderly patients may be more likely to have decreased hepatic or renal function and may be taking multiple medications. Therefore, particular caution is warranted regarding drug interactions and monitoring of adverse effects. Dose selection should be made carefully, taking into account the greater frequency of decreased organ function in this population.

Missed Dose

Adherence to the prescribed regimen is critically important in HIV treatment. Missing doses can allow the virus to replicate and develop resistance mutations, potentially limiting future treatment options. If you miss a dose:

• Once-daily dosing: If less than 12 hours have passed since the scheduled time, take the missed dose with food along with your pharmacokinetic enhancer as soon as possible. If more than 12 hours have passed, skip the missed dose and resume your normal schedule.
• Twice-daily dosing: If less than 6 hours have passed since the scheduled time, take the missed dose with food along with ritonavir as soon as possible. If more than 6 hours have passed, skip the missed dose and take the next dose at the regular time.
• Never take a double dose to compensate for a missed one.

Overdose

There is no specific antidote for darunavir overdose. In the event of overdose, general supportive measures are recommended, including monitoring of vital signs and observation of the patient’s clinical status. If indicated, elimination of unabsorbed darunavir may be achieved by emesis or gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since darunavir is highly protein-bound, dialysis is unlikely to be beneficial in significantly removing the drug from the bloodstream. Contact a poison control center or emergency services in case of suspected overdose.

What Are the Side Effects of Darunavir Accord?

Like all medicines, Darunavir Accord can cause side effects. The most common side effects include diarrhea, nausea, headache, rash, and abdominal pain. Most side effects are mild to moderate. Serious but rare side effects include hepatotoxicity, severe skin reactions (Stevens-Johnson syndrome), and pancreatitis. Report any unusual symptoms to your doctor immediately.

The safety profile of darunavir has been extensively characterized through large clinical trials (ARTEMIS, ODIN, TITAN, POWER, DUET) involving thousands of patients. The following side effect information is based on these pivotal studies and post-marketing surveillance data reported to regulatory agencies including the EMA and FDA. Side effects are categorized by frequency according to international convention.

How Should You Store Darunavir Accord?

Store Darunavir Accord tablets below 30°C (86°F) in the original packaging to protect from moisture. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of antiretroviral medicines is essential to maintain their effectiveness throughout the treatment period. Darunavir Accord film-coated tablets should be stored at controlled room temperature, not exceeding 30°C (86°F). The tablets should be kept in their original blister packaging or container until the time of use, as this protects them from moisture and light degradation.

Do not store Darunavir Accord in the bathroom, near a sink, or in any location with high humidity, as moisture can affect the stability and integrity of the film coating. When traveling, keep the tablets in a cool, dry place and avoid exposing them to extreme temperatures, such as in a car glove compartment during summer months.

Check the expiry date on the packaging before taking each dose. Do not use the medicine if the expiry date has passed or if the tablets appear discolored, crumbled, or damaged. Return any unused or expired medication to your pharmacist for safe disposal — do not flush medicines down the toilet or throw them in household waste, as this can harm the environment.

What Does Darunavir Accord Contain?

Each Darunavir Accord 400 mg film-coated tablet contains 400 mg of the active substance darunavir (as darunavir ethanolate). The tablets also contain several inactive ingredients (excipients) that are necessary for the manufacturing process and to ensure tablet stability.

The active substance is darunavir, present as darunavir ethanolate. Each 400 mg film-coated tablet contains darunavir ethanolate equivalent to 400 mg of darunavir. Darunavir ethanolate is a white to off-white powder with limited aqueous solubility.

The tablet core typically contains the following excipients: colloidal anhydrous silica, microcrystalline cellulose, crospovidone, magnesium stearate, and hypromellose. The film coating contains a mixture of polyvinyl alcohol (partially hydrolyzed), titanium dioxide (E171), macrogol/PEG, talc, and iron oxide yellow (E172) or iron oxide red (E172), depending on the specific formulation. These excipients are standard pharmaceutical ingredients used in many oral solid dosage forms.

Patients with known intolerances to any of these excipients should inform their doctor or pharmacist before starting treatment. The tablets do not contain lactose, gluten, or animal-derived gelatin, making them suitable for patients with these specific dietary restrictions. However, always check the patient information leaflet for the most up-to-date excipient list, as formulations may vary between batches or manufacturing sites.

Frequently Asked Questions About Darunavir Accord

References

Editorial Team